InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: dr_lowenstein post# 43424

Tuesday, 03/27/2018 11:45:07 PM

Tuesday, March 27, 2018 11:45:07 PM

Post# of 48316
Actually TNBC has an extremely low response rate even with checkpoint therapy so the Oncosec therapy of ep-il12 seems to be priming the immune sytstem for a robsut response to Opdivo. That is why the Oncosec abstract for AACR is currently embargoed....it is very exciting news and is the reason why Oncosec is planning to speed ahead with a phase II combo study for TNBC following the AACR conference. They are holding a special meeting to reveal their plans after the abstract presentation.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News